Vener, Claudia; Banzi, Rita; Ambrogi, Federico; Ferrero, Annalisa; Saglio, Giuseppe; Pravettoni, Gabriella; Sant, Milena published an article in 2020, the title of the article was First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis.Product Details of 380843-75-4 And the article contains the following content:
Meta-anal. of. Imatinib, the first tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia (CML), improves overall survival (OS), but the introduction of newer TKIs requires the definition of the optimal first-line TKI for newly diagnosed Philadelphia chromosome-pos. (Ph+) chronic-phase CML. This systematic review of randomized controlled trials compares the efficacy and safety of imatinib vs second-generation (dasatinib, nilotinib, bosutinib) and third-generation TKIs (ponatinib) in adults with newly diagnosed Ph+ CP CML, concentrating on OS, progression-free survival, and hematol. and nonhematol. adverse events. The quality of the evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation method. Two RCTs (imatinib vs nilotinib and imatinib vs dasatinib) found no difference in 5-yr OS or PFS. Second- and third-generation TKIs improved 3-mo major mol. responses (relative risk, 4.28; 95% confidence interval [RR], and other efficacy outcomes, decreased accelerated/blastic-phase transformations, but were associated with more cases of thrombocytopenia cardiovascular events and pancreatic and hepatic effects. GRADE showed that the certainty of the evidence ranged from high to moderate. This study shows that, in comparison with imatinib, second- and third-generation TKIs improve clin. responses, but the safer toxicity profile of imatinib may make it a better option for patients with comorbidities. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Product Details of 380843-75-4
The Article related to meta analysis chronic myeloid leukemia tki imatinib dasatinib ponatinib, Placeholder for records without volume info and other aspects.Product Details of 380843-75-4
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics